Curis(US:CRIS)2026-03-19 21:32Financial Data and Key Metrics Changes - Curis reported a net income of $19.4 million or $1.23 per share for Q4 2025, compared to a net loss of $9.6 million or $1.25 per share for the same period in 2024, primarily due to a $27.2 million one-time non-cash gain from the sale of Erivedge [10] - For the year ended December 31, 2025, the net loss was $7.6 million or $0.58 per share, a significant improvement from a net loss of $43.4 million or $6.88 per share in 2024 [10] - Research and development expenses decreased to $5.8 million in Q4 2025 from $9 million in Q4 2024, and for the year, they were $28.3 million compared to $38.6 million in 2024 [11] - General and administrative expenses also decreased to $2.9 million in Q4 2025 from $3.4 million in Q4 2024, totaling $14 million for the year compared to $16.8 million in 2024 [11] Business Line Data and Key Metrics Changes - The company is making progress in its Take Aim Lymphoma study for primary CNS lymphoma, with expectations for accelerated submissions to the FDA and EMA [4] - Curis is expanding studies of emavusertib into additional NHL subtypes, particularly focusing on its potential to change the treatment paradigm for CLL patients [5][6] Market Data and Key Metrics Changes - The company is actively enrolling patients in its registrational study for PCNSL, with expectations to complete enrollment within 12-18 months [23] - Initial data from the ongoing AML triplet study showed that five of eight evaluable patients achieved MRD conversion, indicating potential for deeper responses [8][9] Company Strategy and Development Direction - Curis is prioritizing its resources towards NHL studies, particularly PCNSL, while also initiating a proof of concept study in CLL [15] - The company aims to improve treatment outcomes by combining emavusertib with existing therapies to achieve deeper responses and potentially complete remission for patients [6][42] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress in clinical trials and the potential for significant advancements in 2026, particularly in the registrational study for PCNSL and the proof of concept study in CLL [9] - The company anticipates no meaningful revenue in 2026 due to the cessation of cash flows from Erivedge, but believes it has sufficient cash to fund operations into the second half of 2027 [12][29] Other Important Information - Curis has received initial gross proceeds of $20.2 million from financing in January 2026, with expectations for additional proceeds from warrant exercises [12] Q&A Session Summary Question: How is the company prioritizing trial progress between pivotal PCNSL versus CLL and AML? - Management indicated that resources are being prioritized towards NHL, particularly PCNSL, while CLL is in the early stages of study [14][15] Question: Can you provide updates on enrollment for PCNSL? - Management stated that enrollment is on track, with expectations for full enrollment within 12-18 months [23] Question: Should revenue modeling for 2026 reflect no meaningful revenue? - Management confirmed that there will be no meaningful revenue in 2026, as cash flows from Erivedge have ended [29] Question: What kind of data should be expected at ASH 2026 regarding CLL? - Management indicated that they hope to present meaningful data at ASH, focusing on the potential for deeper responses in patients [39][40]